Shattuck Labs
Shattuck Labs, Inc operates as a biotechnology company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $103m | Private Placement VC | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 202 % | (98 %) | 154 % | 245 % | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (146 %) | (15848 %) | (5306 %) | (1341 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (150 %) | (15636 %) | (5268 %) | (1318 %) | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 188 % | 12715 % | 4485 % | 1175 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Shattuck Labs is a biotechnology company specializing in the development of bi-functional fusion proteins through its proprietary Agonist Redirected Checkpoint (ARC) technology. The company focuses on creating advanced therapeutic solutions that target both clinically validated and emerging pathways. Shattuck Labs serves clients in the healthcare and pharmaceutical sectors, aiming to provide best-in-class and first-in-class therapies. The company operates in the biopharmaceutical market, leveraging its robust drug pipeline of over 300 fusion proteins to address unmet medical needs. Shattuck Labs generates revenue through the development, licensing, and commercialization of its proprietary therapies. The business model includes partnerships with other pharmaceutical companies and research institutions to advance its drug candidates through clinical trials and regulatory approvals.
Keywords: biotechnology, fusion proteins, ARC technology, therapeutic solutions, healthcare, pharmaceutical, drug pipeline, licensing, commercialization, clinical trials.